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Abstract
MicroRNAs (miRNAs) are small RNA molecules that affect cellular processes by controlling gene 
expression. Recent studies have shown that hypoxia downregulates Drosha and Dicer, key 
enzymes in miRNA biogenesis, causing a decreased pool of miRNAs in cancer, and resulting in 
increased tumor growth and metastasis. Here, we demonstrate a previously unrecognized 
mechanism by which hypoxia downregulates Dicer. We found that miR-630, which is upregulated 
under hypoxic conditions, targets and downregulates Dicer expression. In an orthotopic mouse 
model of ovarian cancer, delivery of miR-630 using DOPC nanoliposomes resulted in increased 
tumor growth and metastasis and decreased Dicer expression. Treatment with the combination of 
anti-miR-630 and anti-vascular endothelial growth factor antibody in mice resulted in rescue of 
Dicer expression and significantly decreased tumor growth and metastasis. These results indicate 
that targeting miR-630 is a promising approach to overcome Dicer deregulation in cancer. As 
demonstrated in the study, use of DOPC nanoliposomes for anti-miR delivery serves as a better 
alternative approach to cell line based overexpression of sense or anti-sense miRNAs, while 
avoiding potential in vitro selection effects. Findings from this study provide a new understanding 
of miRNA biogenesis downregulation observed under hypoxia and suggest therapeutic avenues to 
target this dysregulation in cancer.
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Introduction
MicroRNAs (miRNAs) are evolutionarily conserved small RNA molecules that are involved 
in gene regulation by targeting mRNA to suppress gene expression3, 5, 13. Dicer and Drosha, 
two key enzymes involved in miRNA biogenesis pathways, are downregulated in several 
types of cancer which is associated with poor patient survival9, 16. Recently, our group 
reported that decreased Drosha and Dicer levels lead to downregulation of miRNA 
biogenesis in cancer22, 27. In the current report, we show a novel mechanism by which 
miR-630, which is upregulated under hypoxic conditions, regulates Dicer expression by 
directly targeting the Dicer 3’ untranslated region (UTR). We demonstrate that miR-630 
increases tumor growth and metastasis when delivered via a 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) nanoliposome miRNA delivery platform, which is currently being 
tested in clinical trials. When anti-vascular endothelial growth factor (VEGF) therapy 
(known to induce hypoxia) was combined with anti-miR-630 therapy, Dicer expression was 
rescued, leading to reduction in tumor growth and metastasis.
Results
Hypoxia-upregulated miR-630 targets Dicer
In a previous study, we reported that Drosha and Dicer are downregulated under hypoxic 
conditions, and ETS1/ELK1-mediated transcriptional repression is the mechanism of Drosha 
downregulation22. While investigating Dicer downregulation under hypoxia conditions, we 
observed a significant decrease in Dicer 3’UTR luciferase reporter activity in cells exposed 
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to hypoxia (Figure 1A, Supp. Figure 1A). The decrease in 3’UTR activity prompted us to 
examine whether miRNAs are responsible for Dicer regulation under hypoxic conditions. To 
determine the specific miRNAs that are potentially involved in the downregulation of Dicer, 
we performed an integrative analysis using publicly available miRNA target prediction 
software and a miRNA array22 that compares miRNA expression under normoxic and 
hypoxic conditions. From the array of upregulated miRNAs, we identified 10 miRNAs that 
have potential miRNA target sites in the 3’UTR of Dicer (Figure 1B). To validate these 
findings, we performed quantitative real-time polymerase chain reaction (PCR) with these 
upregulated miRNAs from the miRNA microarray, and 8 miRNAs showed significantly 
increased expression in A2780 ovarian cancer cells exposed to hypoxia (Figure 1C).
We subsequently transfected these 8 miRNA mimics into A2780 cells. Only miR-630 
resulted in a decrease in Dicer mRNA and protein expression (Figure 1D, Supp. Figure 1B), 
indicating a potential role for miR-630 in targeting Dicer. We tested upregulation of 
miR-630 in additional cell lines, including the ovarian cancer cell line OVCAR3 and the 
breast cancer cell line MCF7. In both cell types, we observed consistent increases in 
miR-630 expression after exposure to hypoxia (Supp. Figure 1C). Upon transfecting anti-
miR-630 into cells exposed to hypoxia, we observed significant rescue of Dicer expression 
(Figure 1D, Supp. Figure 1D).
To determine the definitive role of miR-630–mediated downregulation of Dicer, we 
performed a Dicer 3’UTR assay with mutated 3’ UTR miR-630 binding site with or without 
transfection of miR-630. Data showed a significant reduction in luciferase reporter activity 
in cells treated with miR-630 compared with cells treated with control miRNA in wild type 
3” UTR cells (Figure 1E, Supp. Figure 1E). In cells with a mutation in the Dicer 3’UTR 
region that corresponds to the miR-630 binding region, the effect of miR-630 on Dicer 
3’UTR luciferase reporter activity after transfection with the miR-630 mimic was abrogated 
(Figure 1E, Supp. Figure 1E).
Quantification of precursor miR-630 showed increased expression of pri-miR-630 under 
hypoxic conditions, suggesting that miR-630 is transcriptionally upregulated (Supp. Figure 
2A). Deep sequencing mRNA data A2780 from cells treated with hypoxia22 were cross-
referenced with the miR-630 promoter analysis to potentially identify transcription factors 
that could regulate miR-630 expression. STAT1 was identified as a transcription factor that 
binds directly to the promoter region of miR-630 (Supp. Figure 2B) and potentially leads to 
increased precursor levels of miR-630. Under hypoxic conditions, phospo-STAT1 levels 
were increased significantly at the mRNA and protein levels (Supp. Figure 2C). Use of 
siRNA-mediated gene silencing led to significant STAT1 gene knockdown (Supp. Figure 
2D). Expression of miR-630 was significantly reduced under hypoxic conditions when cells 
were treated with siSTAT1 (Supp. Figure 2E), and a corresponding rescue in Dicer 
expression levels (Supp. Figure 2F) was also observed. Upon chromatin hybridization and 
immunoprecipitation (ChIP) assay with STAT1 antibody, we observed significant binding of 
STAT1 to miR-630 promoter region. RNA polymerase II ChIP was used as a positive control 
(Supp. Figure 2G).
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MiR-630 expression correlates with hypoxia in vivo and in ovarian cancer clinical samples
Consistent with our in vitro findings, we observed a substantial increase in both precursor 
and mature miR-630 expression levels in tumor samples from the A2780 in vivo model in 
which mice had been treated with a VEGF-targeted antibody (bevacizumab) known to result 
in profound hypoxia in the tumor microenvironment (Figure 2A–B). Next, we examined 30 
human epithelial ovarian cancer samples with known hypoxia profile (15 with high- and 15 
with low levels of hypoxia)22. Data analysis showed a significant positive correlation 
between expression levels of miR-630 and the hypoxia marker CA9 (Figure 2C). In addition, 
we observed a significant negative correlation between miR-630 expression and Dicer levels 
in these clinical samples (Figure 2D).
Next, we interrogated The Cancer Genome Atlas (TCGA) dataset for high grade serous 
ovarian cancer to further investigate the correlation between expression of miR-630 and 
hypoxia-upregulated miR-210, a hypoxia marker. We observed a significant positive 
correlation between these 2 miRNAs (Figure 2E). We next examined the survival difference 
between patients with high and low miR-630 levels in their tumors using the ovarian cancer 
dataset from TCGA. We observed significantly worse overall survival rates in patients 
whose tumors had high levels of miR-630 (Figure 2F). We also examined expression of 
miR-630 using in situ hybridization and CA9 using immunofluorescence in ovarian tumor 
samples (Figure 2G). Microscopically, sections showed co-localization of areas with high 
miR-630 expression in highly hypoxic areas.
MiR-630–mediated Dicer downregulation under hypoxic conditions leads to tumor growth 
in vivo
Previously, we have shown decreases in Dicer and Drosha levels under hypoxic conditions, 
resulting in increased tumor progression via enhanced epithelial-to-mesenchymal transition 
(EMT). In this context, we tested the phenotypic effect of miR-630 downregulation in cells 
under normoxic and hypoxic conditions. When miR-630 was transfected into cells under 
normoxic conditions, cells showed significant increases in migration and invasion (Figure 
3A–B). Inhibiting miR-630 under hypoxic conditions led to increased Dicer expression and 
a significant decrease in migration and invasion (Figure 3A–B).
We also analyzed expression of E-cadherin and vimentin, two EMT markers, after 
introducing miR-630 under normoxic conditions or anti-miR-630 under hypoxic conditions. 
Data showed significant induction of EMT upon introduction of miR-630 under normoxic 
conditions, and this effect was reversed by treatment with anti-miR-630 under hypoxic 
conditions (Figure 3C).
To understand the biological implications of miR-630–mediated Dicer downregulation under 
hypoxic conditions, we delivered miR-630 incorporated in DOPC nanoliposomes to A2780 
tumor-bearing mice. There was a significant increase in tumor weight and distant metastases 
following treatment with miR-630-DOPC (Figure 3D–H). Interestingly, rare metastases such 
as lung metastases were observed in the miR-630 treatment group (Figure 3G, dotted circle). 
We also observed metastases in other sites, including the omentum and the liver, in the 
miR-630 treatment group, whereas minimal metastases were observed in the control group 
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(Figure 3H). Decreased Dicer RNA and protein expression was observed in tumors from 
mice treated with miR-630 (Figure 3I).
We next sought to explore combinations of anti-miR-630 and anti-VEGF therapy. Mice were 
treated with bevacizumab after tumor establishment, and we observed a significant increase 
in tumor weight and the number of metastatic nodules in the bevacizumab treatment group 
(Figure 4A–D). In mice treated with anti-miR-630 in addition to bevacizumab, we observed 
significant reductions in tumor weight and the number of metastatic nodules compared with 
mice treated with bevacizumab alone (Figure 4A–D). A significant reduction in metastatic 
spread was observed in the anti-miR-630 treatment group compared with the control group 
(Figure 4D). In addition, a significant increase in CA9 expression was observed in mice that 
received anti-VEGF therapy compared with control mice (Figure 4E). Importantly, we noted 
rescue of Dicer expression in the anti-miR-630 treatment group (Figure 4F).
Discussion
Here, we show a previously unrecognized mechanism by which hypoxia downregulates 
Dicer, a key enzyme in miRNA biogenesis. We provide evidence that miR-630, which is 
transcriptionally upregulated under hypoxic conditions, targets and decreases Dicer 
expression. In an orthotopic mouse model of ovarian cancer, delivery of miR-630 using 
DOPC nanoparticles resulted in increased tumor growth and metastasis and decreased Dicer 
expression. Treatment with the combination of anti-VEGF and anti-miR-630 in the mice 
resulted in rescue of Dicer expression and significantly decreased tumor growth and 
metastasis.
During progression, tumor cells encounter significant hypoxia owing to abnormal 
vasculature7. Emerging studies have shown that hypoxia is involved in promoting tumor 
progression and resistance to therapy7, 23. Direct assessment of tumor hypoxia in patient 
samples has demonstrated worse clinical outcomes in patients whose tumors had high levels 
of hypoxia28. In addition, emerging data suggest that anti-VEGF therapies in current clinical 
use induce significant hypoxia in tumors14, 31. We observed that short-term anti-VEGF 
therapy results in potential “angiogenesis rebound,” resulting in increased cancer growth and 
metastasis22.
Global downregulation of miRNAs under hypoxic conditions has been reported. However, 
thus far, studies have shown that only a few miRNAs are upregulated under hypoxic 
conditions, and most of these are not well characterized. One of the well-studied miRNAs 
that is upregulated under hypoxic conditions is miR-210, a transcriptional target of HIF1-
α8, 10. Target analysis has shown that miR-210 downregulates SDHD, leading to 
stabilization of HIF1-α21 and an apoptosis-inducing factor called mitochondrion-associated 
3 (AIFM3), known to induce cell death17.
In the current study, we report a novel role of miR-630, which is also upregulated under 
hypoxic conditions. Previously, miR-630 was shown to modulate apoptosis in cells treated 
with cisplatin by decreasing DNA damage and promoting cell survival6. However, the 
mechanism by which this occurs has not been identified. Another recent study showed that 
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miR-630 targets SLUG, resulting in reduced invasion11. Our study significantly broadens the 
understanding of how miR-630 can enhance tumor metastasis, suggesting distinctive role of 
miR-630 in cells under exposure to hypoxia. Through several lines of evidence, we showed 
that miR-630 is able to target Dicer and is responsible for hypoxia-mediated tumor 
progression and metastasis. Even though we observed significant reduction in metastasis 
upon treatment with anti-miR-630 compared to anti-VEGF therapy alone, these effects could 
be driven by additional genes, which are rescued by anti-miR-630 and require further 
investigation. Hypoxia signaling involves multiple cell types within tumor 
microenvironment and the effect of anti-miR-630 on these cells such as endothelial cells 
remain to be investigated.
We and others have shown that decreased expression of Drosha and Dicer in cancer is 
associated with poor clinical outcomes4, 9, 16, 24, 25. Mechanisms for Drosha downregulation 
include transcriptional downregulation via c-myc29 and ADARB11. For Dicer, direct binding 
of Tap63 transcription factor to the Dicer promoter has been shown to downregulate Dicer, 
as has loss of TAp63 in cancer25. Two independent studies have shown different miRNAs 
targeting Dicer, specifically miR-103/10715 and let-726. Previously, we reported that a 
significant number of miRNAs were affected by hypoxia-mediated Dicer downregulation, 
and we showed the mechanism by which this downregulation leads to increased tumor 
progression22, 27. In these studies, we reported that Dicer is downregulated in breast cancer 
cells exposed to hypoxia via an epigenetic mechanism involving oxygen deprivation–
mediated inhibition of KDM6A/B, a demethylase enzyme. However, understanding of Dicer 
downregulation in cancer has thus far been limited to a few studies showing involvement of 
specific miRNAs such as let7 and miR-103/107 or transcriptional regulation by 
TAp6315, 25, 26. These studies do not consider the influence of the tumor microenvironment 
on Dicer downregulation. In contrast, we show in the current report that hypoxia-induced 
downregulation of miRNA biogenesis is a highly dynamic process22, 27. Our study not only 
sheds light on the mechanism by which hypoxia regulates Dicer, but also suggests that 
miRNA/RNAi-based gene targeting may be a useful strategy to develop therapies targeting 
genes that cannot be treated using classic chemical agents or antibodies18–20. As 
demonstrated in our study, the DOPC liposome-anti-miRNA system for in vivo delivery acts 
as a promising therapeutic approach to rescue the expression of Dicer in cancer.
In summary, our study provides a clear mechanistic link between hypoxia and tumor 
progression via upregulation of miR-630 and downregulation of Dicer. These findings could 
translate into the development of new therapeutic approaches that target deregulated miRNA 
biogenesis in cancer.
Methods
Cell line maintenance and siRNA and miRNA transfections
All cancer cell lines were maintained at 37°C in 5% CO2. Ovarian cancer (A2780 and 
OVCAR3) and breast cancer (MCF7) cancer cell lines were obtained from the American 
Type Culture Collection. Cells and were maintained in culture with RPMI-1640 
supplemented with 10–15% fetal bovine serum (FBS) and 0.1% gentamicin sulfate (Gemini 
Bioproducts, Calabasas, CA). Cell lines were tested routinely to confirm the absence of 
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mycoplasma, and in vitro experiments were conducted with cultures at 60–80% confluence. 
All siRNA transfections were performed using RNAiMAX (Invitrogen, Carlsbad, CA) 
reagent following the forward transfection protocol from the manufacturer. To minimize 
toxicity, media was changed five hours after transfections. For hypoxia treatments, cells 
were incubated in an oxygen-controlled hypoxia chamber at 1% O2. Sequences for siRNAs 
are as follows: siDicer1 S 5’ CAUUGAUCCUGUCAUGGAU [dT] [dT] 3’ AS 5’ 
AUCCAUGACAGGAUCAAUG [dT] [dT] 3’ siDicer2 S 5’ 
GCAGUUAUGAUUUAGCUAA [dT] [dT] 3’ AS 5’ UUAGCUAAAUCAUAACUGC [dT] 
[dT] 3’, siSTAT1-1 1 S 5’ CUCAUUCCGUGGACGAGGU [dT] [dT] 3’ AS 5’ 
ACCUCGUCCACGGAAUGAG [dT] [dT] 3’ siSTAT1-2 S 5’ 
CCUGAUUAAUGAUGAACUA [dT] [dT] 3’ AS 5’ UAGUUCAUCAUUAAUCAGG [dT] 
[dT] 3’.
In vivo models
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY). Animals 
were cared for according to guidelines set forth by the American Association for 
Accreditation of Laboratory Animal Care and the US Public Health Service policy on 
Human Care and Use of Laboratory Animals. Mouse studies were approved and supervised 
by The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use 
Committee. At the time of injection, all animals were 8–12 weeks old.
Orthotopic models of ovarian cancer were developed as described previously2, 30. For all 
animal experiments, cells were harvested using trypsin-EDTA, neutralized with FBS-
containing media, washed, and resuspended to the appropriate cell number in Hanks’ 
balanced salt solution (HBSS; Gibco, Carlsbad, CA) prior to injection. A2780 cells were 
directly injected into the ovary (0.8 × 106 cells in a 1:1 mixture of BD Matrigel and HBSS 
with a total volume of 100 µL of HBSS). For the intra-ovarian injections, mice were 
anesthetized with ketamine and xylazine. A small skin incison was made incision and 
dissection performed to visualize the right ovary. A 1-mL tuberculin syringe with a 30-gauge 
needle was used to inject the cell suspension directly into the ovary. Incisions were closed 
with surgical clips, and the mouse was returned to a cage until fully recovered. For all 
therapeutic experiments, a dose of 200 µg miRNA/kg was used, as described 
previously12, 20, 30. Twice weekly treatments via intraperitoneal injections commenced one 
week after cell inoculation and continued for four weeks. Mice were randomized and treated 
with miRNA incorporated in neutral DOPC nanoliposomes (intraperitoneal administration). 
Control groups received scrambled miRNA controls of same quantity. For the anti-VEGF 
therapy experiment, mice were allowed to develop tumors for two to three weeks, and twice 
weekly treatments with bevacizumab (6.25 mg/kg) were administered via intraperitoneal 
administration. For all experiments, once a mouse in any group became moribund, all groups 
were sacrificed, necropsied, and tumors were harvested. Tumor weight, number, and 
location of tumor nodules were recorded. Tumor tissue was either fixed in formalin for 
paraffin embedding, frozen in optimal cutting temperature media, or snap-frozen.
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Liposomal nanoparticle preparation
MiRNA for in vivo delivery was incorporated into DOPC, as previously described12. DOPC 
and miRNA were mixed in the presence of excess tertiary butanol at a ratio of 1:10 (w/w) 
miRNA. Tween-20 was added in a ratio of 1:19. The mixture was vortexed, frozen in an 
acetone/dry ice bath, and lyophilized. Before in vivo administration, preparations were 
hydrated with phosphate-buffered saline at room temperature for a concentration of 200 µg 
miRNA per injection.
Tumor samples
Patient tumor samples were obtained as per the previously approved protocol16. We obtained 
75 specimens of invasive epithelial ovarian cancer from The University of Texas MD 
Anderson Cancer Center Tumor Bank. For use as normal control, 15 benign ovarian 
epithelial samples were also obtained. Frozen tumor samples (approximately 0.2 mg each) 
were used for RNA isolation.
TCGA data and bioinformatics analysis
Agilent 44K gene expression, Agilent human miRNA microarray 8×15K miRNA expression 
data, and clinical information were obtained from the open access and controlled-access tiers 
of the TCGA data portal with NIH approval. Alignment of sample identifiers yielded 456 
tumor cases with all information available at the time of data retrieval from the TCGA. 
Pearson correlation test, Kaplan-Meier, and Mantel-Cox survival analyses were performed 
using R 2.10.0. Significance was defined as p < 0.05.
Target gene binding sites, luciferase reporter assays, and Dicer 3’UTR site mutagenesis
The putative miRNA binding sites on Dicer 3’UTR were predicted bioinformatically using 
several algorithms for predicting miRNA targets. This was done using the following publicly 
available sites: http://www.microrna.org for the miRanda algorithm, http://
www.targetscan.org for the TargetScan algorithm, http://genie.weizmann.ac.il/pubs/mir07 
for the PITA algorithm, http://cbcsrv.watson.ibm.com for the RNA22 algorithm, http://
diana.cslab.ece.ntua.gr/microT for the microT algorithm, and http://genome.ucsc.edu/cgi-
bin/hgTables?command=start with http://pictar.mdc-berlin.de/ for the PicTar algorithm. The 
predicted miRNAs were shortlisted by cross-referencing miRNA data from the miRNA array 
(GSE52744). GoClone pLightSwitch luciferase reporters for the 3’UTR regions of Dicer 
were obtained from SwitchGear Genomics (Menlo Park, CA).
A2780 and MCF7 cells were transfected with FuGENE HD TFX reagent in a 96-well plate 
with scrambled control and miR-630 mimics (100nM; Ambion) along with the 3’UTR 
reporter gene and Cypridina TK control construct (pTK-Cluc). After 24 hours of 
transfection, luciferase activity was obtained with the LightSwitch Dual Luciferase assay 
kits using a microplate luminometer per manufacturer guidelines (Biotek). Luciferase 
activity was normalized using the Cypridina TK control construct, and an empty luciferase 
reporter vector was used as a negative control. The ratios obtained were further normalized 
according to the scrambled control. Mutants of the Dicer 3’UTR were generated using the 
QuikChange Lightning Multi Site-direct Mutagenesis kit (Agilent Technologies), using the 
primers (F 
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5’TGATGCAGATAAAGCAGGAAGGACCTCGGGTAAATGTCACTTACATATAAATGC
AGCATTCCACGAAGCATCAAGTT3’) to mutate five base pairs within the miR-630 
binding site. Mutagenesis was confirmed using Sanger DNA sequencing prior to luciferase 
assays.
Immunoblotting
Protein lysates from cultured cells were prepared using modified RIPA buffer (50mM Tris-
HCl [pH 7.4], 150mM NaCl, 1% Triton, 0.5% deoxycholate) plus 25 µg/mL leupeptin, 10 
µg/mL aprotinin, 2 mM EDTA, and 1 mM sodium orthovandate. Protein concentrations were 
determined using a BCA Protein Assay Reagent kit (Pierce Biotechnology, Rockford, IL). 
Lysates were loaded and separated on sodium dodecyl sulfate–polyacrylamide gels. Using 
semidry electrophoresis, proteins were transferred overnight to a nitrocellulose membrane,
(Bio-Rad Laboratories, Hercules, CA) blocked with 5% bovine serum albumin for one hour, 
and incubated at 4°C overnight with primary antibody (Dicer [Novus Biologicals, Littleton, 
Colorado], STAT1, and pSTAT1 [Cell Signalling, Danvers, MA]). After washing with tris-
buffered saline with Tween-20, membranes were incubated with horseradish peroxidase 
(HRP)–conjugated horse anti-mouse or rabbit IgG (1:2000; GE Healthcare) for two hours. 
Visualized of HRP was achieved by using an enhanced chemiluminescence detection kit 
(Pierce Biotechnology). To confirm equal loading of samples, blots were probed with an 
antibody specific for β-actin (0.1 µg/mL; Sigma)
Chromatin hybridization and immunoprecipitation assay
Cells were cultured in hypoxic or normoxic conditions for 48 h and chromatin 
immunoprecipitation assays were performed using the Chip-it express kit (Active Motif), as 
described by the manufacturer. In brief, cross-linked cells were collected, lysed, sonicated 
and subjected to immunoprecipitation with the STAT1, RNA Pol II antibodies or IgG isotype 
control. Immunocomplexes were collected with protein A/G agarose magnetic beads and 
eluted. Cross-links were reversed by incubation at 65 °C with high salt concentration. PCR-
based quantification of percentage of input STAT1 binding on the miR-630 promoter region 
was performed. The 3,000 base upstream region of the STAT1 binding region was used as a 
control.
Quantitative real-time PCR
Total RNA was isolated using the Qiagen RNeasy kit (Qiagen). For miRNA quantification, 
total RNA was isolated using the Trizol/isopropanol total RNA precipitation method. Using 
1000 ng of RNA, cDNA was synthesized using a Verso cDNA kit (Thermo Scientific), as 
per manufacturer instructions. Analysis of mRNA levels was performed on a 7500 Fast 
Real-Time PCR System (Applied Biosystems) with SYBR Green-based real-time PCR for 
all genes. Dicer and Drosha Taqman assays (Life Technologies) were performed. Semi-
quantitative real-time PCR was done with reverse-transcribed RNA and 100 ng/µL sense and 
antisense primers in a total volume of 20 µL. Total RNA was isolated using Trizol 
(Invitrogen) extraction. For pri-miRNA and mature miRNA quantifications, Taqman miRNA 
assays (Life Technologies) were used and reverse-transcription real-time PCR was 
performed, according to the manufacturer’s instructions. RNU6B (for mature miRNAs) or 
18S (pri- and precursor miRNAs) were used as housekeeping genes. Primer sequences are as 
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follows: 18S: F 5’CGCCGCTAGAGGTGAAATTC3’ R 5’TTGGCAAATGCTTTCGCTC3’, 
STAT1: F 5’TGAATATTCCCCGACTGAGC3’ R 5’AGGAAGACCCAATCCAGATGT3’, 
miR630 ChIP: F 5’TGTGCCTTATTCACTGTTCCC3’ R 
5’TGGGCTCATTCACAGTTCCC3’, Negative control ChIP: F 5’ 
TCTTCCAAGCAGCCCTAAAG3’ R 5’ CAAGCATGGCCCTGTTATAC3’.
Migration and invasion assays
Modified Boyden chambers (Coster, Boston, MA) coated with 0.1% gelatin (migration) or 
extracellular matrix components (invasion) were used. A2780 cells (1 × 105) suspended in 
100 µL of serum-free media were added into the upper chamber 24 hours after miRNA/
siRNA transfections. Complete media containing 10% FBS (500 µL) was added to the 
bottom chamber as a chemo-attractant for cells. Chambers were incubated at 37°C in 5% 
CO2 for six hours (migration) or overnight (invasion). After incubation, cells in the upper 
chamber were removed with cotton swabs. Cells were fixed and stained and counted using 
light microscopy. Cells from five random fields were counted.
In situ hybridization and immunofluorescence staining
Deparrafinization and rehydration of the formalin-fixed, paraffin-embedded tissue sections 
used xylene and an ethanol dilution series. Sections of tissue sections were digested with 15 
µg/mL proteinase K for 20 minutes at room temperature and loaded onto Ventana Discovery 
Ultra for in situ hybridization analysis. Tissue slides were incubated with double-DIG 
labeled mercury LNA microRNA probe (exiqon) for two hours at 55°C. Three percent H2O2 
was used to inactivate endogenous peroxidases. Following polyclonal anti-DIG antibody and 
HRP-conjugated secondary antibody (Ventana) incubation, tyramine-conjugated 
fluorochrome (TSA) reaction was performed for twelve minutes. Sequential TSA rounds 
were performed for the detection of proteins using the same protocol. Slides were mounted 
with antifading ProLong Gold Solution (Life Technologies).
Statistical analyses
Microsoft Excel or GraphPad Prism was used to analyze data. Continuous variables were 
compared using the Student's t-test or analysis of variance, and the Mann–Whitney test was 
used to compare differences. Using two-way analysis of variance, we determined that a 
sample size of 10 animals per group would provide an effective size of 1.3 with 80% power 
at a significance level of P=0.05. We considered P<0.05 to be statistically significant. All 
statistical analyses were expressed as mean±standard error of the mean.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Dicer is downregulated under hypoxic conditions via direct targeting of miR-630
(A) Relative Dicer 3’ untranslated region (UTR) and promoter luciferase reporter activity 
under hypoxic conditions in A2780 cells. β-actin 3’UTR or promoter was used as a control. 
(B) Expression profiles of significantly deregulated (p < 0.5) miRNAs in A2780 cells 
exposed to hypoxia. MicroRNAs (miRNAs) were profiled using a miRNA microarray of 
RNA extracted from A2780 cells exposed to hypoxia for 48 hours. The box shows miRNAs 
upregulated under hypoxic conditions and predicted to target Dicer 3’UTR, with the 
corresponding fold change and the number of independent software predictions. (C) Levels 
of mature miRNAs predicted to target Dicer 3’UTR, profiled using quantitative real-time 
polymerase chain reaction of RNA from A2780 cells exposed to hypoxia for 48 hours. (D) 
Expression of Dicer in A2780 cells after transfecting the cells with miR-630 under normoxic 
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conditions or with anti-miR-630 under hypoxic conditions. (E) Dicer 3’UTR wild type (WT) 
and miR-630 binding site mutant (Mut) luciferase activity in A2780 cells transfected with 
miR-630 or control miRNA. Data are presented as mean ± standard error of the mean of n ≥ 
3 independent experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t test).
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Figure 2. miR-630 expression correlates with hypoxia in vivo and in clinical samples of ovarian 
cancer
(A) Hypoxia marker GLUT1, (B) Precursor and (C) mature miRNA-630 levels in A2780 
mouse tumor samples treated with anti-VEGF agent bevacizumab. Pearson correlation 
graphs comparing (D) hypoxia marker CA9 with miR-630 expression levels and (E) 
miR-630 with Dicer expression levels in clinical tumor samples (n = 15 with high hypoxia 
levels and n = 15 with low hypoxia levels). (F) Pearson correlation between miR-630 and 
hypoxia-upregulated miR-210 in high-grade serous ovarian cancer clinical samples from 
The Cancer Genome Atlas (TCGA) dataset. (G) Overall disease-specific probability of 
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survival in patients with high-grade serous ovarian cancer based on tumoral expression of 
miR-630. Data from the high-grade serous ovarian cancer dataset in TCGA were analyzed. 
(H) Co-staining of miR-630 and CA9 in tumor samples from patients with ovarian cancer. In 
situ hybridization was used to visualize miR-630 and immunofluorescent staining was used 
for CA9. Scale bar: 200µm. Data are presented as mean ± standard error of the mean of n ≥ 
3 independent experimental groups. *p < 0.05, **p < 0.01 (Student t test).
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Figure 3. Hypoxia-upregulated miR-630 is involved in increased tumor progression
(A) Migration and (B) invasion of A2780 cancer cells transfected with control microRNA 
(miRNA) or miR-630 under normoxic conditions or transfected with control mRNA or anti-
miR-630 under hypoxic conditions. (C) Expression of epithelial-to-mesenchymal transition 
markers E-cadherin and vimentin in A2780 cancer cells transfected with control miRNA or 
miR-630 under normoxic conditions or control miRNA or anti-miR-630 under hypoxic 
conditions. (D–F) Aggregate tumor mass, number of distant metastatic nodules, and photon 
counts in A2780 tumors from mice treated with control miRNA or miR-630 (n = 10 mice 
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per group). (G) Representative luminescence pictures showing tumor burden (top) and 
photographs of a rare metastatic nodule in the miR-630 group (bottom). (H) Pattern of 
metastatic spread in mice treated with control miRNA or miR-630. (I) mRNA and protein 
expression levels of Dicer in A2780 tumor samples from mice treated with control miRNA 
or miR-630. Scale bar: 200µm. Data are presented as mean ± standard error of the mean of n 
≥ 3 independent experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t test).
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Figure 4. Treatment with the combination of a vascular endothelial growth factor (VEGF) 
antibody (bevacizumab) and anti-miR-630 results in decreased tumor growth and metastasis
(A–B) Aggregate tumor weight and number of distant metastatic nodules in mice treated 
with bevacizumab and anti-miR-630 (n = 5 mice per group). (C) Representative pictures of 
tumor burden in all treatment groups. (D) Distribution of metastatic nodules in all treatment 
groups. (E–F) Hypoxia marker CA9 and Dicer mRNA expression levels in tumor samples 
from each treatment group. Data are presented as mean ± standard error of the mean of n ≥ 3 
experimental groups. *p < 0.05, **p < 0.01, ***p < 0.001 (Student t test).
Rupaimoole et al. Page 19
Oncogene. Author manuscript; available in PMC 2016 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
